Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
11-dehydrocorticosterone + beta-NADPH
corticosterone + beta-NADP+
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
11beta-hydroxytestosterone + NAD+
11-oxotestosterone + NADH
-
-
-
?
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
1beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, no reductase activity in aldosterone-sensitive collecting duct
-
-
ir
2 7-oxocholesterol + 2 NADPH + 2 H+
7beta-hydroxycholesterol + 7alpha-hydroxycholesterol + 2 NADP+
isozyme 11beta-HSD1, stereospecific reaction
-
-
?
7-oxocholesterol + NADPH + H+
7beta-hydroxycholesterol + NADP+
corticosterone + beta-NAD+
11-dehydrocorticosterone + beta-NADH
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
cortisol + beta-NAD+
cortisone + beta-NADH
cortisol + NAD+
cortisone + NADH
cortisol + NAD+
cortisone + NADH + H+
cortisone + beta-NADPH
cortisol + beta-NADP+
cortisone + NADPH + H+
cortisol + NADP+
dexamethasone + NAD+
11-dehydromethasone + NADH
additional information
?
-
11-dehydrocorticosterone + beta-NADPH
corticosterone + beta-NADP+
low activity
-
-
r
11-dehydrocorticosterone + beta-NADPH
corticosterone + beta-NADP+
-
higher activity
-
-
r
11-dehydrocorticosterone + beta-NADPH
corticosterone + beta-NADP+
-
higher activity
-
-
r
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1, low activity
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1
-
-
?
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
-
i.e. cortisol
i.e. cortisone
?
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
-
i.e. cortisol
i.e. cortisone
-
r
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone
-
-
r
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, clear but not exclusive preference for NAD+, only oxidative activity
-
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, significant higher rate of conversion for 11-beta-HSD2 than for 11-beta-HSD1
-
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone
-
-
?
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, no enzyme activity in reverse reaction direction
-
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
-
i.e. corticosterone
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
-
i.e. corticosterone
-
?
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
-
isoform 11beta-HSD2
-
r
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
-
i.e. corticosterone
-
r
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
-
i.e. cortisone
i.e. cortisol
ir
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
-
important role in modulating mineralocorticoid and glucocorticoid receptor occupancy by glucocorticoids
i.e. cortisol
ir
7-oxocholesterol + NADPH + H+
7beta-hydroxycholesterol + NADP+
-
isozyme 11beta-HSD1, stereospecific reaction, very low activity
-
-
?
7-oxocholesterol + NADPH + H+
7beta-hydroxycholesterol + NADP+
isozyme 11beta-HSD1, stereospecific reaction, very low activity
-
-
?
7-oxocholesterol + NADPH + H+
7beta-hydroxycholesterol + NADP+
isozyme 11beta-HSD1, stereospecific reaction
-
-
?
7-oxocholesterol + NADPH + H+
7beta-hydroxycholesterol + NADP+
-
isozyme 11beta-HSD1, stereospecific reaction
-
-
?
7-oxocholesterol + NADPH + H+
7beta-hydroxycholesterol + NADP+
-
isozyme 11beta-HSD1, stereospecific reaction
-
-
?
corticosterone + beta-NAD+
11-dehydrocorticosterone + beta-NADH
-
-
-
r
corticosterone + beta-NAD+
11-dehydrocorticosterone + beta-NADH
-
-
-
-
r
corticosterone + beta-NAD+
11-dehydrocorticosterone + beta-NADH
-
-
-
-
r
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
-
-
-
?
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
-
-
-
ir
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
-
-
-
ir
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
11beta-HSD2
-
-
ir
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
-
-
-
?
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
-
-
-
ir
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
isozyme 11beta-HSD2
-
-
?
cortisol + beta-NAD+
cortisone + beta-NADH
-
-
-
r
cortisol + beta-NAD+
cortisone + beta-NADH
higher activity
-
-
r
cortisol + beta-NAD+
cortisone + beta-NADH
-
-
-
-
r
cortisol + beta-NAD+
cortisone + beta-NADH
-
low activity
-
-
r
cortisol + beta-NAD+
cortisone + beta-NADH
-
-
-
-
r
cortisol + beta-NAD+
cortisone + beta-NADH
-
low activity
-
-
r
cortisol + NAD+
cortisone + NADH
-
-
-
?
cortisol + NAD+
cortisone + NADH
-
pathway overview
-
-
ir
cortisol + NAD+
cortisone + NADH
-
-
-
-
ir
cortisol + NAD+
cortisone + NADH
-
-
-
-
?
cortisol + NAD+
cortisone + NADH
-
-
-
-
ir
cortisol + NAD+
cortisone + NADH
-
-
-
-
r
cortisol + NAD+
cortisone + NADH
-
-
-
?
cortisol + NAD+
cortisone + NADH
-
oxidase that inactivates glucocorticoids to their 11-oxo derivatives
-
-
?
cortisol + NAD+
cortisone + NADH
-
inactivation of the biologically active glucocorticoid
-
-
r
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2
-
-
?
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the oxidative reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2, inactivation of cortisol, which interacts with the mineralocorticoid receptor, isozyme 11beta-HSD2 inhibition leads to stimulation of sodium and water reabsorption and to an increase of the intravascular volume that suppresses renin and secondarily an increase of blood pressure
-
-
?
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction 11beta-HSD1 with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction of 11-beta-HSD1 with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
-
-
-
?
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 highly prefers the oxidation of cortisol
-
-
r
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 is involved in inactivation of glucocorticoids, forskolin is involved in regulation of isozyme 11beta-HSD2 via intracellular cAMP
-
-
ir
cortisol + NAD+
cortisone + NADH
-
-
-
-
?
cortisol + NAD+
cortisone + NADH
-
-
-
-
r
cortisol + NAD+
cortisone + NADH
-
levels of cortisol oxidation are comparable in the presence of either NADP+ or NAD+
-
-
?
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction of 11beta-HSD1 with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH + H+
-
-
-
-
?
cortisol + NAD+
cortisone + NADH + H+
-
-
-
-
?
cortisone + beta-NADPH
cortisol + beta-NADP+
low activity
-
-
r
cortisone + beta-NADPH
cortisol + beta-NADP+
-
higher activity
-
-
r
cortisone + beta-NADPH
cortisol + beta-NADP+
-
higher activity
-
-
r
cortisone + NADPH + H+
cortisol + NADP+
-
isozyme 11beta-HSD1, activation
-
-
?
cortisone + NADPH + H+
cortisol + NADP+
-
isozyme 11beta-HSD1, low activity
-
-
r
cortisone + NADPH + H+
cortisol + NADP+
isozyme 11beta-HSD1, activation
-
-
?
cortisone + NADPH + H+
cortisol + NADP+
isozyme 11beta-HSD1, high activity
-
-
r
cortisone + NADPH + H+
cortisol + NADP+
isozyme 11beta-HSD1, activation
-
-
?
cortisone + NADPH + H+
cortisol + NADP+
isozyme 11beta-HSD1, preferred substrate, high activity
-
-
r
cortisone + NADPH + H+
cortisol + NADP+
isozyme 11beta-HSD1, activation
-
-
?
cortisone + NADPH + H+
cortisol + NADP+
isozyme 11beta-HSD1, high activity
-
-
r
cortisone + NADPH + H+
cortisol + NADP+
-
isozyme 11beta-HSD1
-
-
r
cortisone + NADPH + H+
cortisol + NADP+
-
isozyme 11beta-HSD1, activation
-
-
?
cortisone + NADPH + H+
cortisol + NADP+
-
isozyme 11beta-HSD1
-
-
r
cortisone + NADPH + H+
cortisol + NADP+
-
isozyme 11beta-HSD1, activation
-
-
?
dexamethasone + NAD+
11-dehydromethasone + NADH
-
isoform 11beta-HSD2
-
ir
dexamethasone + NAD+
11-dehydromethasone + NADH
-
isoform 11-beta-HSD2 shows significantly higher rate of conversion than isoform 11-betaHSD1
-
-
ir
additional information
?
-
the enzyme plays a role in spermatogenesis
-
-
?
additional information
?
-
-
enzyme inhibition affects the glucocorticoid- and dexamethasone-mediated regulation of surfactant protein A metabolism, overview
-
-
?
additional information
?
-
-
proinflammatory cytokines inhibit placental isozyme 11beta-HSD2 activity through Ca2+ and cAMP pathways, overview
-
-
?
additional information
?
-
-
effects of hypertension on cardiac steroid metabolism, overview
-
-
?
additional information
?
-
-
estradiol has a regulatory function on the isozymes in the liver, isozyme 11beta-HSD1 expression is about 30% reduced in castrated male rats, while expression of isozyme 11beta-HSD2 is increased, overview
-
-
?
additional information
?
-
the enzyme plays a role in control of cortisol and spermatogenesis
-
-
?
additional information
?
-
-
physiological role of 11beta-hydroxysteroid dehydrogenase in limiting any local actions of glucocorticoids within the reproductive tissues
-
-
?
additional information
?
-
-
maximal rates for NADP+-dependent cortisol oxidation are 7.4-28.5fold greater than the Vmax for NADPH-dependent reduction of cortisone, and are comparable with the rates of NAD+-dependent cortisol metabolism
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
11beta-hydroxytestosterone + NAD+
11-oxotestosterone + NADH
-
-
-
?
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
1beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, no reductase activity in aldosterone-sensitive collecting duct
-
-
ir
corticosterone + beta-NAD+
11-dehydrocorticosterone + beta-NADH
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
cortisol + beta-NAD+
cortisone + beta-NADH
cortisol + NAD+
cortisone + NADH
cortisone + NADPH + H+
cortisol + NADP+
additional information
?
-
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1
-
-
?
11-dehydrocorticosterone + NADPH
corticosterone + NADP+
-
isozyme 11beta-HSD1
-
-
?
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
-
i.e. cortisol
i.e. cortisone
?
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
-
i.e. cortisol
i.e. cortisone
-
r
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone
-
-
r
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, clear but not exclusive preference for NAD+, only oxidative activity
-
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, significant higher rate of conversion for 11-beta-HSD2 than for 11-beta-HSD1
-
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone
-
-
?
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH
-
i.e. corticosterone, no enzyme activity in reverse reaction direction
-
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
-
i.e. corticosterone
-
ir
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
-
i.e. corticosterone
-
?
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
-
isoform 11beta-HSD2
-
r
11beta,21-dihydroxypregn-4-en-3,20-dione + NAD+
21-hydroxy-pregn-4-en-3,11,20-trione + NADH + H+
-
i.e. corticosterone
-
r
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
-
i.e. cortisone
i.e. cortisol
ir
17,21-dihydroxy-pregn-4-ene-3,11,20-trione + NADH
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione + NAD+
-
important role in modulating mineralocorticoid and glucocorticoid receptor occupancy by glucocorticoids
i.e. cortisol
ir
corticosterone + beta-NAD+
11-dehydrocorticosterone + beta-NADH
-
-
-
r
corticosterone + beta-NAD+
11-dehydrocorticosterone + beta-NADH
-
-
-
-
r
corticosterone + beta-NAD+
11-dehydrocorticosterone + beta-NADH
-
-
-
-
r
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
-
-
-
?
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
-
-
-
ir
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
-
-
-
ir
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
-
-
-
?
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
-
-
-
ir
corticosterone + NAD+
11-dehydrocorticosterone + NADH + H+
-
isozyme 11beta-HSD2
-
-
?
cortisol + beta-NAD+
cortisone + beta-NADH
-
-
-
r
cortisol + beta-NAD+
cortisone + beta-NADH
-
-
-
-
r
cortisol + beta-NAD+
cortisone + beta-NADH
-
-
-
-
r
cortisol + NAD+
cortisone + NADH
-
-
-
?
cortisol + NAD+
cortisone + NADH
-
pathway overview
-
-
ir
cortisol + NAD+
cortisone + NADH
-
-
-
-
ir
cortisol + NAD+
cortisone + NADH
-
-
-
-
ir
cortisol + NAD+
cortisone + NADH
-
oxidase that inactivates glucocorticoids to their 11-oxo derivatives
-
-
?
cortisol + NAD+
cortisone + NADH
-
inactivation of the biologically active glucocorticoid
-
-
r
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the oxidative reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2, inactivation of cortisol, which interacts with the mineralocorticoid receptor, isozyme 11beta-HSD2 inhibition leads to stimulation of sodium and water reabsorption and to an increase of the intravascular volume that suppresses renin and secondarily an increase of blood pressure
-
-
?
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction 11beta-HSD1 with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 catalyzes the reverse reaction of 11-beta-HSD1 with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction with cofactor NAD+
-
-
ir
cortisol + NAD+
cortisone + NADH
-
-
-
-
?
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 highly prefers the oxidation of cortisol
-
-
r
cortisol + NAD+
cortisone + NADH
-
isozyme 11beta-HSD2 is involved in inactivation of glucocorticoids, forskolin is involved in regulation of isozyme 11beta-HSD2 via intracellular cAMP
-
-
ir
cortisol + NAD+
cortisone + NADH
-
-
-
-
?
cortisol + NAD+
cortisone + NADH
isozyme 11beta-HSD2 catalyzes the reverse reaction of 11beta-HSD1 with cofactor NAD+
-
-
ir
cortisone + NADPH + H+
cortisol + NADP+
-
isozyme 11beta-HSD1, activation
-
-
?
cortisone + NADPH + H+
cortisol + NADP+
isozyme 11beta-HSD1, activation
-
-
?
cortisone + NADPH + H+
cortisol + NADP+
isozyme 11beta-HSD1, activation
-
-
?
cortisone + NADPH + H+
cortisol + NADP+
isozyme 11beta-HSD1, activation
-
-
?
cortisone + NADPH + H+
cortisol + NADP+
-
isozyme 11beta-HSD1, activation
-
-
?
cortisone + NADPH + H+
cortisol + NADP+
-
isozyme 11beta-HSD1, activation
-
-
?
additional information
?
-
the enzyme plays a role in spermatogenesis
-
-
?
additional information
?
-
-
enzyme inhibition affects the glucocorticoid- and dexamethasone-mediated regulation of surfactant protein A metabolism, overview
-
-
?
additional information
?
-
-
proinflammatory cytokines inhibit placental isozyme 11beta-HSD2 activity through Ca2+ and cAMP pathways, overview
-
-
?
additional information
?
-
-
effects of hypertension on cardiac steroid metabolism, overview
-
-
?
additional information
?
-
-
estradiol has a regulatory function on the isozymes in the liver, isozyme 11beta-HSD1 expression is about 30% reduced in castrated male rats, while expression of isozyme 11beta-HSD2 is increased, overview
-
-
?
additional information
?
-
the enzyme plays a role in control of cortisol and spermatogenesis
-
-
?
additional information
?
-
-
physiological role of 11beta-hydroxysteroid dehydrogenase in limiting any local actions of glucocorticoids within the reproductive tissues
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1S,2R,3S,5R,6R)-4-methylidene-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]heptane-2,3,5-triol
-
-
(1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aR,6S,8aR)-6-hydroxy-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol
-
-
(1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol
-
-
(2E,4S)-4-hydroxy-5-[(1S,5S,6S)-6-(hydroxymethyl)-2-methylidenebicyclo[3.1.1]hept-6-yl]-2-methylpent-2-enoic acid
-
-
(2S)-5-(acetyloxy)-2-hydroxypentyl acetate
-
-
(3alpha,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid
-
-
(3alpha,18beta,20beta)-3-(acetylamino)-11-oxo-olean-12-en-29-oicacid
-
-
(3alpha,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid
-
-
(3alpha,18beta,20beta)-3-methylsulfonylamino-11-oxo-olean-12-en-29-oic acid
-
-
(3beta)-3-(acetyloxy)-11-oxoolean-12-en-30-oic acid
-
-
(3beta)-3-hydroxy-11-oxoolean-12-en-30-amide
-
-
(3beta)-3-hydroxy-18,29-epoxyolean-12-ene-11,29-dione
IC50 value for isoform 11beta-HSD2 above 25 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(3beta)-3-hydroxyandrost-5-en-17-one
-
treatment of rats induces a shift from isoform 11beta-HSD1 to 11beta-HSD2 expression, increasing conversion from active to inactive glucocorticoids. Dehydroepiandrosterone likely modulates the transcription of 11beta-HSD2 in a phosphatidylinositol-3 kinase/Akt-dependent manner by increasing CCAAT/enhancer-binding protein beta mRNA and protein expression
(3beta)-3-[(3-carboxypropanoyl)oxy]urs-12-en-28-oic acid
IC50 value for isoform 11beta-HSD2 above 3 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(3beta)-30-[hydroxy(methyl)amino]-11,30-dioxoolean-12-en-3-yl acetate
IC50 value for isoform 11beta-HSD1 above 1 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(3beta)-N,3-dihydroxy-11-oxoolean-12-en-30-amide
-
-
(3beta,18beta,20beta)-11-oxo-3-succinylamino-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3,N-dihydroxy-N-methyl-11-oxo-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-(2-carboxy-ethylsulfonylamino)-11-oxoolean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-(2-methoxycarbonyl-ethylsulfonylamino)-11-oxo-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-(acetylamino)-11-oxo-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-acetoxy-N-hydroxy-11-oxo-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-acetoxy-N-methoxy-11-oxo-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-acetoxy-N-methyl-N-hydroxy-11-oxoolean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-acetylamino-N-hydroxy-N-methyl-11-oxoolean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-amino-11-oxoolean-12-en-29-oic acid, diphenylmethyl ester
-
-
(3beta,18beta,20beta)-3-hydroxy-N-methoxy-11-oxo-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-3-methylsulfonylamino-11-oxo-olean-12-en-29-oic acid
-
-
(3beta,18beta,20beta)-N-hydroxy-N-methyl-11-oxo-3-[(trifluoromethylsulfonyl)amino]-olean-12-en-29-amide
-
-
(3beta,18beta,20beta)-N-hydroxy-N-methyl-3-methoxyamino-11-oxo-olean-12-en-29-amide
-
-
(3E)-3-(methoxyimino)-11-oxoolean-12-en-30-oic acid
-
-
(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-4,4,6a,6b,8a,11,14b-heptamethyl-11-[(methylsulfonyl)amino]-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl acetate
IC50 value for isoform 11beta-HSD1 above 40 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites
(4aS,5R,8aR)-5,6-bis(hydroxymethyl)-1,1,4a-trimethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-3,4,4a,5,8,8a-hexahydronaphthalen-2(1H)-one
11-Dehydrocorticosterone
-
inhibition of isozyme 11beta-HSD2
11-dehydrocortisterone
-
-
11-oxo-3beta,5alpha-tetrathydrotestosterone
-
-
11-oxo-allopregnanolone
-
inhibition of both isozymes 11beta-HSD1 and of isozyme 11beta-HSD2
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione
-
i.e. cortisol
11beta,21-dihydroxypregn-4-en-3,20-dione
-
11-beta-HSD2, 50% inhibition at 0.00001 mM
11beta-hydroxy-allopregnanolone
-
-
11beta-hydroxyandrostanediol
-
-
11beta-hydroxyandrostenedione
-
-
11beta-hydroxyprogesterone
-
-
11beta-hydroxytestosterone
-
inhibition of both isozymes 11beta-HSD1 and of isozyme 11beta-HSD2
17beta-estradiol
-
decrease in isoform HSD2 protein in male, but not female, fetal lung explant
18beta-glycyrrhetinic acid
-
inhibits both 11beta-HSD1 and 11beta-HSD2, but preferentially inhibits 11beta-HSD2
2-oxopentane-1,5-diyl diacetate
3,11-dioxoolean-12-en-30-oic acid
-
-
3-((3r,5r,7r)-adamantan-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3,4,7-trimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3,4-dimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3,5-dimethyladamantylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3-bromotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3-fluorotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(3-phenyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)tricyclo[3.3.1.13,7]decan-1-ol
3-(adamantan-1-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine
3-(tricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
-
IC50 in the presence of NADP+: 0.12 mM, IC50 in the presence of NAD+: 5.6 mM; i.e. CHAPS
3alpha,5alpha-tetrahydro-11-dehydrocorticosterone
-
-
3alpha,5alpha-tetrahydro-dehydrocortisterone
-
-
3alpha,5alpha-tetrahydroaldosterone
-
-
3alpha,5alpha-tetrahydrocorticosterone
-
inhibition of isozyme 11beta-HSD1 and isozyme isozyme 11beta-HSD2
3alpha,5alpha-tetrahydrocortisol
-
-
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
4-n-octylphenol
-
inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0235 mM
4-nonylphenol
-
inhibition of liver isozyme 11beta-HSD1 and kidney isozyme 11beta-HSD2, 11beta-HSD1 IC50: 49.3 mM, isozyme 11beta-HSD2 IC50: 0.0203 mM
4-pregnen-11,17-diol-3,20-dione
-
IC50: 0.00035 mM
4-pregnen-11alpha-ol-3,20-dione
-
IC50: 0.0001 mM
4-pregnen-11beta-ol-3,20-dione
-
IC50: 0.00005 mM
4-pregnen-16alpha-ol-3,20-dione
-
not inhibitory
4-pregnen-17,21-diol-3,20-dione
-
not inhibitory
4-pregnen-17alpha,20alpha-diol-3-one
-
not inhibitory
4-pregnen-17alpha-ol-3,20-dione
-
IC50: 0.047 mM
4-pregnen-20alpha-ol-3-one
-
IC50: 0.007 mM
4-pregnen-20beta-ol-3-one
-
IC50: 0.008 mM
4-pregnen-21-ol-3,20-dione
-
IC50: 0.001 mM
4-pregnen-3,11,20-trione
-
IC50: 0.0004 mM
4-pregnen-3,20-dione
-
IC50: 0.0011 mM
4-t-octylphenol
-
inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0089 mM
5-hydroxy-4-oxopentyl acetate
5-pregnen-3beta,11beta-diol-20-one
-
IC50: 0.0001 mM
5alpha-dihydrocorticosterone
-
-
5alpha-pregnan-11alpha-ol-3,20-dione
-
IC50: 0.00035 mM
5alpha-pregnan-11beta,17alpha,21-triol-3,20-dione
-
IC50: 0.0031 mM
5alpha-pregnan-11beta,21-diol-3,20-dione
-
IC50: 0.00015 mM
5alpha-pregnan-3alpha,11beta,17alpha,21-tetrol-20-one
-
IC50: 0.008 mM
5alpha-pregnan-3alpha,11beta,21-triol-20-one
-
IC50: 0.00026 mM
5alpha-pregnan-3alpha,11beta-diol-20-one
-
IC50: 0.00012 mM
5alpha-pregnan-3alpha,17alpha,21-triol-11,20-dione
-
IC50: 0.0055 mM
5alpha-pregnan-3alpha,21-diol-11,20-dione
-
IC50: 0.0008 mM
5alpha-Pregnan-3alpha,21-diol-20-one
-
IC50: 0.0024 mM
5alpha-pregnan-3alpha-ol-20-one
-
IC50: 0.008 mM
5beta-pregnan-3alpha,11alpha-diol-20-one
-
not inhibitory
5beta-pregnan-3alpha,11beta,17alpha,21-tetrol-20-one
-
not inhibitory
5beta-pregnan-3alpha,11beta,21-triol-20-one
-
not inhibitory
5beta-pregnan-3alpha,11beta-diol-20-one
-
not inhibitory
5beta-Pregnan-3alpha,21-diol-20-one
-
not inhibitory
5beta-Pregnan-3alpha-ol-20-one
-
not inhibitory
A23187
-
inhibits isozyme 11beta-HSD2 strongly
BVT-14225
-
isozyme 11beta-HSD1 IC50: 52 nM, 1000fold less potent against isozyme 11beta-HSD2
Cd2+
the ERK1/2 inhibitor U0126 can block cadmium-induced inhibition of placental 11beta-HSD2. Cadmium does not alter activities of p38 MAPK, JNK, or PI3 kinase. Cadmium specifically activates the ERK1/2 signaling pathway in human trophoblast cells
cholic acid
-
IC50: 3.529 mM
curcumin
inhibitory against isoform 11beta-HSD2 in intact cells with IC50 value of 14.56 microM
estradiol
-
50% inhibition, DTT protects at 10 mM, estradiol has a regulatory function on the isozymes in the liver
Ethacrynic acid
-
IC50: 0.452 mM
forskolin
-
slight inhibitory effect in absence of interleukin-1beta
Furosemide
-
IC50: 0.059 mM, competitive
interleukin-1beta
-
inhibits isozyme 11beta-HSD2, forskolin acts antagonistically strongly
-
interleukin-1beta or tissue necrosis factor-alpha simultaneously increase 11beta-HSD1 expression and down-regulate 11beta-HSD2
-
mono (2-ethylhexyl) phthalate
mono-(2-ethylhexyl) phthalate
-
mono-(2-ethylhexyl) phthalate inhibits mRNA level and enzyme activity of 11beta-HSD2 in LbetaT2 cells at 0.0001 mM
n-alkyl-substituted adamantyl triazoles
-
NADP+
-
50% inhibition at 220 nmol
naringenin
-
IC50: 0.336 mM
naringin
-
IC50: 2.373 mM
Nifed
-
inhibits isozyme 11beta-HSD2 slightly
perfluorooctane sulfonate
Phenylbutazone
-
IC50: 1.358 mM
sistosterol
-
IC50: 1.395 mM
SQ-22536
-
inhibits isozyme 11beta-HSD2
sterenin A
-
isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205
sterenin B
-
isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205
sterenin C
-
isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205
sterenin D
-
isoindoline alkaloid inhibitor isolated from Stereum sp. SANK 21205
stigmasterol
-
IC50: 1.968 mM
tributyltin
-
inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0165 mM
Triphenyltin
-
inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0033 mM
(+)-gossypol
-
potent inhibitor of 11betaHSD2
(+)-gossypol
-
potent inhibitor of 11betaHSD2
(+/-)-gossypol
-
potent inhibitor of 11betaHSD2
(+/-)-gossypol
-
potent inhibitor of 11betaHSD2
(-)-gossypol
-
potent inhibitor of 11betaHSD2
(-)-gossypol
-
potent inhibitor of 11betaHSD2
(4aS,5R,8aR)-5,6-bis(hydroxymethyl)-1,1,4a-trimethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
-
-
(4aS,5R,8aR)-5,6-bis(hydroxymethyl)-1,1,4a-trimethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
-
-
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
-
-
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
-
-
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-3,4,4a,5,8,8a-hexahydronaphthalen-2(1H)-one
-
-
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-3,4,4a,5,8,8a-hexahydronaphthalen-2(1H)-one
-
-
11-deoxycorticosterone
-
-
11-deoxycorticosterone
-
IC50: 0.001 mM
2'-hydroxyflavanone
-
-
2-oxopentane-1,5-diyl diacetate
-
-
2-oxopentane-1,5-diyl diacetate
-
-
3-((3r,5r,7r)-adamantan-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 74 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-((3r,5r,7r)-adamantan-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 74 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3,4,7-trimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 180 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3,4,7-trimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 180 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3,4-dimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 13 nM, isozyme 11beta-HSD2 IC50: 0.00255 mM
3-(3,4-dimethyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 13 nM, isozyme 11beta-HSD2 IC50: 0.00255 mM
3-(3,5-dimethyladamantylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 36 nM, isozyme 11beta-HSD2 IC50: 0.0176 mM
3-(3,5-dimethyladamantylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 36 nM, isozyme 11beta-HSD2 IC50: 0.0176 mM
3-(3-bromotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 23 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3-bromotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 23 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3-fluorotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 37 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3-fluorotricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 37 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(3-phenyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 2.3 nM, isozyme 11beta-HSD2 IC50: 23 nM
3-(3-phenyltricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 2.3 nM, isozyme 11beta-HSD2 IC50: 23 nM
3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)tricyclo[3.3.1.13,7]decan-1-ol
isozyme 11beta-HSD1 IC50: 739 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)tricyclo[3.3.1.13,7]decan-1-ol
isozyme 11beta-HSD1 IC50: 739 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(adamantan-1-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine
isozyme 11beta-HSD1 IC50: 7.8 nM, isozyme 11beta-HSD2 IC50: above 0.003 mM
3-(adamantan-1-yl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine
isozyme 11beta-HSD1 IC50: 98 nM, isozyme 11beta-HSD2 IC50: above 0.01 mM
3-(tricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 7.7 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3-(tricyclo[3.3.1.13,7]dec-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
isozyme 11beta-HSD1 IC50: 7.7 nM, isozyme 11beta-HSD2 IC50: 0.004 mM
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
-
IC50: 0.254 mM; i.e. glycyrrhetinic acid
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
-
IC50 in the presence of NAD+: 0.000097 mM, IC50 in the presence of NADP+: 0.0003 mM; i.e. glycyrrhetinic acid
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
-
i.e. glycyrrhetinic acid; potent inhibition
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
-
i.e. glycyrrhetinic acid; more effective for 11-dehydrogenase than for 11-oxoreductase activity
5-hydroxy-4-oxopentyl acetate
-
-
5-hydroxy-4-oxopentyl acetate
-
-
abietic acid
-
-
adamantyl triazoles
eight derivatives of different ring size, IC50 of 1.4-2180 nM for isozyme 11beta-HSD1, and of 8.7-2000 nM for isozyme 11beta-HSD2, the IC50 value decreases with increasing ring size, overview
-
adamantyl triazoles
eight derivatives of different ring size, IC50 of 1.4-2180 nM for isozyme 11beta-HSD1, and of 8.7-2000 nM for isozyme 11beta-HSD2, the IC50 value decreases with increasing ring size, overview
-
aldosterone
-
11-beta-HSD2, 50% inhibition at 0.000005 mM
carbenoxolone
-
-
chenodeoxycholic acid
-
-
chenodeoxycholic acid
-
IC50: 0.513 mM
chenodeoxycholic acid
-
-
chenodeoxycholic acid
-
-
di-n-butyl phthalate
-
-
di-n-octyl phthalate
-
-
di-n-pentyl phthalate
-
-
di-n-pentyl phthalate
-
-
dicyclohexyl phthalate
-
inhibition of kidney isozyme 11beta-HSD2, IC50: 0.0465 mM
dicyclohexyl phthalate
-
-
dicyclohexyl phthalate
-
-
diethyl phthalate
-
-
dipropyl phthalate
-
-
flavanone
-
-
glycyrrhetinic acid
-
-
glycyrrhetinic acid
-
strong inhibition of isozyme 11beta-HSD2
interleukin-1beta or tissue necrosis factor-alpha simultaneously increase 11beta-HSD1 expression and down-regulate 11beta-HSD2
-
-
-
interleukin-1beta or tissue necrosis factor-alpha simultaneously increase 11beta-HSD1 expression and down-regulate 11beta-HSD2
-
-
-
mono (2-ethylhexyl) phthalate
-
competitive inhibitor of 11beta-HSD2, possibly via competing with the cofactor NAD+
mono (2-ethylhexyl) phthalate
-
competitive inhibitor of 11beta-HSD2, possibly via competing with the cofactor NAD+
n-alkyl-substituted adamantyl triazoles
substituted with methyl to butyl groups, IC50: of 3-72 nM for isozyme 11beta-HSD1, and of about 0.004 mM for isozyme 11beta-HSD2, overview
-
n-alkyl-substituted adamantyl triazoles
substituted with methyl to butyl groups, IC50: of 3-72 nM for isozyme 11beta-HSD1, and of about 0.004 mM for isozyme 11beta-HSD2, overview
-
perfluorooctane sulfonate
competitive
perfluorooctane sulfonate
-
isoform 11beta-HSD2, competitive
progesterone
-
-
T0504
-
-
additional information
-
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
-
inhibitory effects, antogonistic and agonistic effects of inhibitors and compounds, overview, no inhibition of isozyme 11beta-HSD2 by 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate
-
additional information
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
-
no effect on isoform HSD2 protein level: 5alpha-dihydrotestosterone
-
additional information
-
not inhibited by dimethyl phthalate, butylbenzyl phthalate, di(2-ethylhexyl) phthalate, di-n-heptyl phthalate, diisononyl phthalate, and diisodecyl phthalate
-
additional information
-
18alpha-glycyrrhetinic acid, selective inhibition of 11beta-HSD1, does not inhibit 11beta-HSD2 at concentrations up to 0.02 mM
-
additional information
the JNK inhibitor SP600125 has no effect on 11beta-HSD2 enzyme activity
-
additional information
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
-
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
-
steroid hormones, adrenocorticosteroid derivatives, progesteron and androgen steroid hormones, with 5alpha-ring A reduced-configuration selectively inhibit isozyme 11beta-HSD2, while 5beta-derivatives are inactive
-
additional information
-
isozyme 11beta-HSD1 expression is about 30% reduced in castrated male rats, while expression of isozyme 11beta-HSD2 is increased, overview
-
additional information
-
isozyme 11beta-HSD2 expression is highly reduced in proliferating cells
-
additional information
-
inhibitory effects in intact cells and IC50 values, overview, structure-based pharmacophore models for isozyme 11beta-HSD1 inhibitors using crystal structure 1XU7, 1XU9, and 2 BEL
-
additional information
-
not inhibited by dimethyl phthalate, butylbenzyl phthalate, di(2-ethylhexyl) phthalate, di-n-heptyl phthalate, diisononyl phthalate, and diisodecyl phthalate
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.002 - 0.2
2'-hydroxyflavanone
0.0021 - 0.011
abietic acid
0.00011 - 0.00094
carbenoxolone
0.00055 - 0.035
chenodeoxycholic acid
0.000028 - 0.00044
glycyrrhetinic acid
0.0018
progesterone
-
probably minimal physiological importance
0.002
2'-hydroxyflavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0049
2'-hydroxyflavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.0049
2'-hydroxyflavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0097
2'-hydroxyflavanone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.017
2'-hydroxyflavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.019
2'-hydroxyflavanone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.05
2'-hydroxyflavanone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.2
2'-hydroxyflavanone
above, pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
0.0021
abietic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0039
abietic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.0052
abietic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0061
abietic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0064
abietic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.007
abietic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.007
abietic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.011
abietic acid
pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
0.00011
carbenoxolone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00023
carbenoxolone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.00023
carbenoxolone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00028
carbenoxolone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00034
carbenoxolone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.00035
carbenoxolone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00059
carbenoxolone
pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
0.00094
carbenoxolone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00055
chenodeoxycholic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00077
chenodeoxycholic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0021
chenodeoxycholic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.0021
chenodeoxycholic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0025
chenodeoxycholic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.003
chenodeoxycholic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.02
chenodeoxycholic acid
pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
0.035
chenodeoxycholic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0012
flavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.015
flavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.031
flavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.031
flavanone
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.034
flavanone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.035
flavanone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.054
flavanone
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.2
flavanone
above, pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
0.000028
glycyrrhetinic acid
pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
0.00012
glycyrrhetinic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00012
glycyrrhetinic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00025
glycyrrhetinic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00029
glycyrrhetinic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.0003
glycyrrhetinic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.00033
glycyrrhetinic acid
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00044
glycyrrhetinic acid
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.000006
T0504
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.000015
T0504
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisone reduction
0.000025
T0504
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of 11-dehydrocorticosterone reduction
0.000025
T0504
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00008
T0504
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.000082
T0504
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.00043
T0504
-
pH 7.4, 37°C, isozyme 11beta-HSD1, inhibition of cortisol oxidation
0.0018
T0504
pH 7.4, 37°C, isozyme 11beta-HSD2, inhibition of cortisol oxidation
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00061 - 0.00105
(+)-gossypol
0.00088 - 0.00105
(+/-)-gossypol
0.00133 - 0.0019
(-)-gossypol
0.0000049
(3alpha,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
pH not specified in the publication, 37°C
0.00075
(3beta)-3-(acetyloxy)-11-oxoolean-12-en-30-oic acid
Homo sapiens
-
pH not specified in the publication, 37°C
0.0000029
(3beta)-30-[hydroxy(methyl)amino]-11,30-dioxoolean-12-en-3-yl acetate
Homo sapiens
pH 7.4, 37°C
0.000122
(3beta)-N,3-dihydroxy-11-oxoolean-12-en-30-amide
Homo sapiens
-
pH not specified in the publication, 37°C
0.000458
(3beta,18beta,20beta)-3-(acetylamino)-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
pH not specified in the publication, 37°C
0.0000611
(3beta,18beta,20beta)-3-acetoxy-N-hydroxy-11-oxo-olean-12-en-29-amide
Homo sapiens
-
pH not specified in the publication, 37°C
0.0000029
(3beta,18beta,20beta)-3-acetoxy-N-methyl-N-hydroxy-11-oxoolean-12-en-29-amide
Homo sapiens
-
pH not specified in the publication, 37°C
0.00213
(3beta,18beta,20beta)-3-hydroxy-N-methoxy-11-oxo-olean-12-en-29-amide
Homo sapiens
-
pH not specified in the publication, 37°C
0.0000145
(3beta,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
pH not specified in the publication, 37°C
0.000268
(3E)-3-(methoxyimino)-11-oxoolean-12-en-30-oic acid
Homo sapiens
-
pH not specified in the publication, 37°C
0.0000069
(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-4,4,6a,6b,8a,11,14b-heptamethyl-11-[(methylsulfonyl)amino]-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl acetate
Homo sapiens
pH 7.4, 37°C
0.00047
11-dehydrocortisterone
Ovis aries
-
pH 8.4, 37°C
0.001
11-deoxycorticosterone
Ovis aries aries
-
IC50: 0.001 mM
0.008
11-oxo-3beta,5alpha-tetrathydrotestosterone
Ovis aries
-
pH 8.4, 37°C
0.0015
11-oxo-allopregnanolone
Ovis aries
-
pH 8.4, 37°C
0.0004
11-oxo-progesterone
Ovis aries
-
pH 8.4, 37°C
0.00135
11-oxo-testosterone
Ovis aries
-
pH 8.4, 37°C
0.000061
11beta,17,21-trihydroxy-pregn-4-ene-3,20-dione
Homo sapiens
-
i.e. cortisol, pH and temperature not specified in the publication
0.0000051
11beta,21-dihydroxypregn-4-en-3,20-dione
Homo sapiens
-
pH and temperature not specified in the publication
0.00012
11beta-hydroxy-allopregnanolone
Ovis aries
-
pH 8.4, 37°C
0.0045
11beta-hydroxyandrostanediol
Ovis aries
-
pH 8.4, 37°C
0.0078
11beta-hydroxyandrostenedione
Ovis aries
-
pH 8.4, 37°C
0.00005
11beta-hydroxyprogesterone
Ovis aries
-
pH 8.4, 37°C
0.00035
11beta-hydroxytestosterone
Ovis aries
-
pH 8.4, 37°C
0.000257
18beta-glycyrrhetinic acid
Homo sapiens
-
37°C, pH not specified in the publication
0.000329
3,11-dioxoolean-12-en-30-oic acid
Homo sapiens
-
pH not specified in the publication, 37°C
5.6
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
Homo sapiens
-
pH and temperature not specified in the publication
0.0008
3alpha,5alpha-tetrahydro-dehydrocortisterone
Ovis aries
-
pH 8.4, 37°C
0.0005
3alpha,5alpha-tetrahydroaldosterone
Ovis aries
-
pH 8.4, 37°C
0.00026
3alpha,5alpha-tetrahydrocorticosterone
Ovis aries
-
pH 8.4, 37°C
0.008
3alpha,5alpha-tetrahydrocortisol
Ovis aries
-
pH 8.4, 37°C
0.000097 - 0.254
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
0.0235
4-n-octylphenol
Homo sapiens
-
inhibition of kidney isozyme 11beta-HSD2, pH 7.4, 37°C
0.0203
4-nonylphenol
Homo sapiens
-
inhibition of kidney isozyme 11beta-HSD2, pH 7.4, 37°C
0.00035
4-pregnen-11,17-diol-3,20-dione
Ovis aries aries
-
IC50: 0.00035 mM
0.0001
4-pregnen-11alpha-ol-3,20-dione
Ovis aries aries
-
IC50: 0.0001 mM
0.00005
4-pregnen-11beta-ol-3,20-dione
Ovis aries aries
-
IC50: 0.00005 mM
0.047
4-pregnen-17alpha-ol-3,20-dione
Ovis aries aries
-
IC50: 0.047 mM
0.007
4-pregnen-20alpha-ol-3-one
Ovis aries aries
-
IC50: 0.007 mM
0.008
4-pregnen-20beta-ol-3-one
Ovis aries aries
-
IC50: 0.008 mM
0.001
4-pregnen-21-ol-3,20-dione
Ovis aries aries
-
IC50: 0.001 mM
0.0004
4-pregnen-3,11,20-trione
Ovis aries aries
-
IC50: 0.0004 mM
0.0011
4-pregnen-3,20-dione
Ovis aries aries
-
IC50: 0.0011 mM
0.0089
4-t-octylphenol
Homo sapiens
-
inhibition of kidney isozyme 11beta-HSD2, pH 7.4, 37°C
0.0001
5-pregnen-3beta,11beta-diol-20-one
Ovis aries aries
-
IC50: 0.0001 mM
0.00015
5alpha-dihydrocorticosterone
Ovis aries
-
pH 8.4, 37°C
0.00035
5alpha-pregnan-11alpha-ol-3,20-dione
Ovis aries aries
-
IC50: 0.00035 mM
0.0031
5alpha-pregnan-11beta,17alpha,21-triol-3,20-dione
Ovis aries aries
-
IC50: 0.0031 mM
0.00015
5alpha-pregnan-11beta,21-diol-3,20-dione
Ovis aries aries
-
IC50: 0.00015 mM
0.008
5alpha-pregnan-3alpha,11beta,17alpha,21-tetrol-20-one
Ovis aries aries
-
IC50: 0.008 mM
0.00026
5alpha-pregnan-3alpha,11beta,21-triol-20-one
Ovis aries aries
-
IC50: 0.00026 mM
0.00012
5alpha-pregnan-3alpha,11beta-diol-20-one
Ovis aries aries
-
IC50: 0.00012 mM
0.0055
5alpha-pregnan-3alpha,17alpha,21-triol-11,20-dione
Ovis aries aries
-
IC50: 0.0055 mM
0.0008
5alpha-pregnan-3alpha,21-diol-11,20-dione
Ovis aries aries
-
IC50: 0.0008 mM
0.0024
5alpha-Pregnan-3alpha,21-diol-20-one
Ovis aries aries
-
IC50: 0.0024 mM
0.008
5alpha-pregnan-3alpha-ol-20-one
Ovis aries aries
-
IC50: 0.008 mM
0.00002 - 0.00005
carbenoxolone
0.513
chenodeoxycholic acid
Cavia porcellus
-
IC50: 0.513 mM
3.529
cholic acid
Cavia porcellus
-
IC50: 3.529 mM
0.0089
dexamethasone
Homo sapiens
-
pH and temperature not specified in the publication
0.01369
di-n-butyl phthalate
Rattus norvegicus
-
-
0.03264 - 0.0465
dicyclohexyl phthalate
0.08559
dipropyl phthalate
Rattus norvegicus
-
-
0.452
Ethacrynic acid
Cavia porcellus
-
IC50: 0.452 mM
0.059
Furosemide
Cavia porcellus
-
IC50: 0.059 mM, competitive
0.0000024 - 0.000257
glycyrrhetinic acid
0.00000071
glycyrrhizinic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00000071
glycyrrhizininc acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.1108 - 0.1218
mono (2-ethylhexyl) phthalate
0.0168 - 0.3279
mono-(2-ethylhexyl) phthalate
0.336
naringenin
Cavia porcellus
-
IC50: 0.336 mM
2.373
naringin
Cavia porcellus
-
IC50: 2.373 mM
0.000048 - 0.000293
perfluorooctane sulfonate
1.358
Phenylbutazone
Cavia porcellus
-
IC50: 1.358 mM
1.395
sistosterol
Cavia porcellus
-
IC50: 1.395 mM
0.01
sterenin A
Homo sapiens
-
value above, pH not specified in the publication, 26°C
0.01
sterenin B
Homo sapiens
-
value above, pH not specified in the publication, 26°C
0.01
sterenin C
Homo sapiens
-
value above, pH not specified in the publication, 26°C
0.01
sterenin D
Homo sapiens
-
value above, pH not specified in the publication, 26°C
1.968
stigmasterol
Cavia porcellus
-
IC50: 1.968 mM
0.0165
tributyltin
Homo sapiens
-
inhibition of kidney isozyme 11beta-HSD2, pH 7.4, 37°C
0.0033
Triphenyltin
Homo sapiens
-
inhibition of kidney isozyme 11beta-HSD2, pH 7.4, 37°C
additional information
(1S,2R,3S,5R,6R)-4-methylidene-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]heptane-2,3,5-triol
0.00061
(+)-gossypol
Rattus norvegicus
-
pH and temperature not specified in the publication
0.00105
(+)-gossypol
Homo sapiens
-
pH and temperature not specified in the publication
0.00088
(+/-)-gossypol
Rattus norvegicus
-
pH and temperature not specified in the publication
0.00105
(+/-)-gossypol
Homo sapiens
-
pH and temperature not specified in the publication
0.00133
(-)-gossypol
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0019
(-)-gossypol
Homo sapiens
-
pH and temperature not specified in the publication
0.000097
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
Homo sapiens
-
pH and temperature not specified in the publication
0.254
3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic-acid
Cavia porcellus
-
IC50: 0.254 mM
0.00002
carbenoxolone
Homo sapiens
-
pH and temperature not specified in the publication
0.00005
carbenoxolone
Rattus norvegicus
-
pH and temperature not specified in the publication
0.03264
dicyclohexyl phthalate
Rattus norvegicus
-
-
0.0465
dicyclohexyl phthalate
Homo sapiens
-
inhibition of kidney isozyme 11beta-HSD2, pH 7.4, 37°C
0.0000024
glycyrrhetinic acid
Homo sapiens
-
cell-based assay, pH not specified in the publication, temperature not specified in the publication
0.000257
glycyrrhetinic acid
Homo sapiens
-
pH not specified in the publication, 37°C
0.1108
mono (2-ethylhexyl) phthalate
Homo sapiens
-
-
0.1218
mono (2-ethylhexyl) phthalate
Rattus norvegicus
-
-
0.0168
mono-(2-ethylhexyl) phthalate
Mus musculus
-
11beta-HSD2 from LbetaT2 cell microsomes, in PBS (pH 7.4), at 37°C
0.3279
mono-(2-ethylhexyl) phthalate
Mus musculus
-
11beta-HSD2 from kidney microsomes, in PBS (pH 7.4), at 37°C
0.000048
perfluorooctane sulfonate
Homo sapiens
pH 7.2, 37°C
0.000293
perfluorooctane sulfonate
Rattus norvegicus
-
pH 7.2, 37°C
additional information
(1S,2R,3S,5R,6R)-4-methylidene-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]heptane-2,3,5-triol
Homo sapiens
-
IC50 = 0.0254 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aR,6S,8aR)-6-hydroxy-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol
Homo sapiens
-
IC50 above 0.1 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(1S,2R,5R,6R)-4-(hydroxymethyl)-1-([(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]methyl)-7-oxabicyclo[4.1.0]hept-3-ene-2,5-diol
Homo sapiens
-
IC50 = 0.0015 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(2E,4S)-4-hydroxy-5-[(1S,5S,6S)-6-(hydroxymethyl)-2-methylidenebicyclo[3.1.1]hept-6-yl]-2-methylpent-2-enoic acid
Homo sapiens
-
IC50 = 0.0106 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(2S)-5-(acetyloxy)-2-hydroxypentyl acetate
Homo sapiens
-
IC50 = 0.177 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(3alpha,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid
Homo sapiens
-
50% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3alpha,18beta,20beta)-3-(acetylamino)-11-oxo-olean-12-en-29-oicacid
Homo sapiens
-
4% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3alpha,18beta,20beta)-3-methylsulfonylamino-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
4% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3beta)-3-hydroxy-11-oxoolean-12-en-30-amide
Homo sapiens
-
13% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-11-oxo-3-succinylamino-olean-12-en-29-oic acid
Homo sapiens
-
13% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-11-oxo-3-trifluoromethylsulfonylaminoolean-12-en-29-oic acid
Homo sapiens
-
22% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3,N-dihydroxy-N-methyl-11-oxo-olean-12-en-29-amide
Homo sapiens
-
7% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3-(2-carboxy-ethylsulfonylamino)-11-oxoolean-12-en-29-oic acid
Homo sapiens
-
40% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3-(2-methoxycarbonyl-ethylsulfonylamino)-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
3% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3-acetoxy-N-methoxy-11-oxo-olean-12-en-29-amide
Homo sapiens
-
36% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3-acetylamino-N-hydroxy-N-methyl-11-oxoolean-12-en-29-amide
Homo sapiens
-
4% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3-amino-11-oxoolean-12-en-29-oic acid, diphenylmethyl ester
Homo sapiens
-
42% residual activity at 0,001 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-3-methylsulfonylamino-11-oxo-olean-12-en-29-oic acid
Homo sapiens
-
4% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-N-hydroxy-N-methyl-11-oxo-3-[(trifluoromethylsulfonyl)amino]-olean-12-en-29-amide
Homo sapiens
-
44% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(3beta,18beta,20beta)-N-hydroxy-N-methyl-3-methoxyamino-11-oxo-olean-12-en-29-amide
Homo sapiens
-
30% residual activity at 0,0002 mM, pH not specified in the publication, 37°C
additional information
(4aS,5R,8aR)-5,6-bis(hydroxymethyl)-1,1,4a-trimethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
Homo sapiens
-
IC50 = 0.177 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(4aS,5R,8aR)-5,6-bis(hydroxymethyl)-1,1,4a-trimethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
Mus musculus
-
IC50 = 0.2505 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
Homo sapiens
-
IC50 = 0.22 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-1,2,3,4,4a,5,8,8a-octahydronaphthalen-2-ol
Mus musculus
-
IC50 = 0.3303 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-3,4,4a,5,8,8a-hexahydronaphthalen-2(1H)-one
Homo sapiens
-
IC50 = 0.2 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
(4aS,5S,8aR)-5-(hydroxymethyl)-1,1,4a,6-tetramethyl-3,4,4a,5,8,8a-hexahydronaphthalen-2(1H)-one
Mus musculus
-
IC50 = 0.5002 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
2-oxopentane-1,5-diyl diacetate
Homo sapiens
-
IC50 = 0.0051 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
2-oxopentane-1,5-diyl diacetate
Mus musculus
-
IC50 = 0.0323 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
5-hydroxy-4-oxopentyl acetate
Homo sapiens
-
IC50 = 0.0389 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
5-hydroxy-4-oxopentyl acetate
Mus musculus
-
IC50 = 0.1291 mg/ml, pH not specified in the publication, temperature not specified in the publication
additional information
BVT-14225
Homo sapiens
-
isozyme 11beta-HSD1 IC50: 52 nM, 1000fold less potent against isozyme 11beta-HSD2
additional information
carbenoxolone
Homo sapiens
-
2% residual activity at 0,001 mM, pH not specified in the publication, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Latif, S.A.; Sheff, M.F.; Ribeiro, C.E.; Morris, D.J.
Selective inhibition of sheep kidney 11beta-hydroxysteroid dehydrogenase isoform 2 activity by 5alpha-reduced (but not 5beta) derivates of adrenocorticosteroids
Steroids
62
230-237
1997
Ovis aries aries
brenda
Ferrari, P.; Smith, R.E.; Funder, J.W.; Krozowski, Z.S.
Substrate and inhibitor specificity of the clones human 11beta-hydroxysteroid dehydrogenase type 2 isoform
Am. J. Physiol.
270
E900-904
1996
Homo sapiens
brenda
Alfaidy, N.; Blot-Chabaud, M.; Robic, D.; Kenouch, S.; Bourbouze, R.; Bonvalet, J.P.; Farman, N.
Characteristics and regulation of 11beta-hydroxysteroid dehydrogenase of proximal and distal nephron
Biochim. Biophys. Acta
1243
461-468
1995
Rattus norvegicus
brenda
Blum , S.; Buhler, H.
Characterization of human placental 11beta-hydroxysteroid dehydrogenase, a key enzyme of cortocosteroid metabolism
Cell. Physiol. Biochem.
5
167-175
1995
Homo sapiens
-
brenda
Albiston, A.L.; Obeyesekere, V.R.; Smith, R.E.; Krozowski, Z.S.
Cloning and tissue distribution of the human 11beta-hydroxysteroid dehydrogenase type 2 enzyme
Mol. Cell. Endocrinol.
105
R11-R17
1994
Homo sapiens
brenda
Zhang, Y.D.; Lorenzo, B.; Reidenberg, M.M.
Inhibition of 11beta-hydroxysteroid dehydrogenase obtained from guinea pig kidney by furosemide, naringenin and some other compounds
J. Steroid Biochem. Mol. Biol.
49
81-85
1994
Cavia porcellus
brenda
Lakshim, V.; Nath, N.; Muneyyirci-Delale, O.
Characterization of 11beta-hydroxysteroid dehydrogenase of human placenta: Evidence for the existence of two species of 11beta-hydroxysteroid dehydrogenases
J. Steroid Biochem. Mol. Biol.
45
391-397
1993
Homo sapiens
brenda
Monder, C.
The forms and functions of 11beta-hydroxysteroid dehydrogenase
J. Steroid Biochem. Mol. Biol.
45
161-165
1993
Rattus norvegicus
brenda
Naray-Fejes-Toth, A.; Rusvai, E.; Denault, D.L.; Germain, D.L.St.; Fejes-Toth, G.
Expression and characterization of a new species of 11beta-hydroxysteroid dehydrogenase in Xenopus oocytes
Am. J. Physiol.
265
F896-900
1993
Oryctolagus cuniculus
brenda
Hundertmark, S.; Ragosch, V.; Schein, B.; Buhler, H.; Fromm, M.; Lorenz, U.; Weitzel, H.K.
11-beta-Hydroxysteroid dehydrogenase of rat lung: Enzyme kinetic, oxidase-reductase ration, electrolyte and trace element dependence
Enzyme Protein
47
83-91
1993
Rattus norvegicus
brenda
Gomez-Sanchez, E.P.; Ganjam, V.; Chen, Y.J.; Liu, Y.; Zhou, M.Y.; Toroslu, C.; Romero, D.G.; Hughson, M.D.; de Rodriguez, A.; Gomez-Sanchez, C.E.
Regulation of 11beta-hydroxysteroid dehydrogenase enzymes in the rat kidney by estradiol
Am. J. Physiol.
285
E272-279
2003
Rattus norvegicus
brenda
Holmes, M.C.; Yau, J.L.W.; Kotelevtsev, Y.; Mullins, J.J.; Seckl, J.R.
11beta-Hydroxysteroid dehydrogenases in the brain: two enzymes two roles
Ann. N. Y. Acad. Sci.
1007
357-366
2003
Mus musculus, Rattus norvegicus
brenda
Schipper, L.; Spee, B.; Rothuizen, J.; Woutersen-van Nijnanten, F.; Fink-Gremmels, J.
Characterisation of 11beta-hydroxysteroid dehydrogenases in feline kidney and liver
Biochim. Biophys. Acta
1688
68-77
2004
Felis catus
brenda
Zbankova, S.; Bryndova, J.; Kment, M.; Pacha, J.
Expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in colorectal cancer
Cancer Lett.
210
95-100
2004
Homo sapiens
brenda
Waddell, B.J.; Hisheh, S.; Krozowski, Z.S.; Burton, P.J.
Localization of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in the male reproductive tract
Endocrinology
144
3101-3106
2003
Rattus norvegicus
brenda
Zallocchi, M.L.; Matkovic, L.; Calvo, J.C.; Damasco, M.C.
Adrenal gland involvement in the regulation of renal 11beta-hydroxysteroid dehydrogenase 2
J. Cell. Biochem.
92
591-602
2004
Rattus norvegicus
brenda
Burton, P.J.; Waddell, B.J.
Myometrial expression of 11beta-hydroxysteroid dehydrogenase type 2 in rat pregnancy
J. Endocrinol.
172
519-526
2002
Rattus norvegicus
brenda
Gomez-Sanchez, E.P.; Venkataseshu, G.; Chen, Y.J.; Liu, Y.; Zhou, M.Y.; Toroslu, C.; Romero, D.G.; Hughson, M.D.; de Rodriguez, A.; Gomez-Sanchez, C.E.
Regulation of 11beta-hydroxysteroid dehydrogenase enzymes in the rat kidney by estradiol
Am. J. Physiol. Endocrinol. Metab.
285
E272-E279
2003
Rattus norvegicus
brenda
Kossintseva, I.; Wong, S.; Johnstone, E.; Guilbert, L.; Olson, D.M.; Mitchell, B.F.
Proinflammatory cytokines inhibit human placental 11beta-hydroxysteroid dehydrogenase type 2 activity through Ca2+ and cAMP pathways
Am. J. Physiol. Endocrinol. Metab.
290
E282-E288
2006
Homo sapiens
brenda
Garbrecht, M.R.; Schmidt, T.J.; Krozowski, Z.S.; Snyder, J.M.
11beta-Hydroxysteroid dehydrogenase type 2 and the regulation of surfactant protein A by dexamethasone metabolites
Am. J. Physiol. Endocrinol. Metab.
290
E653-E660
2006
Homo sapiens
brenda
Denari, D.; Ceballos, N.R.
Seasonal changes in the activity of 11 beta-hydroxysteroid dehydrogenase in toad testes
Ann. N. Y. Acad. Sci.
1040
297-300
2005
Rhinella arenarum
brenda
Zhang, J.; Osslund, T.D.; Plant, M.H.; Clogston, C.L.; Nybo, R.E.; Xiong, F.; Delaney, J.M.; Jordan, S.R.
Crystal structure of murine 11 beta-hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes
Biochemistry
44
6948-6957
2005
Mus musculus
brenda
Xiang, J.; Ipek, M.; Suri, V.; Massefski, W.; Pan, N.; Ge, Y.; Tam, M.; Xing, Y.; Tobin, J.F.; Xu, X.; Tam, S.
Synthesis and biological evaluation of sulfonamidooxazoles and beta-keto sulfones: selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I
Bioorg. Med. Chem. Lett.
15
2865-2869
2005
Homo sapiens
brenda
Olson, S.; Aster, S.D.; Brown, K.; Carbin, L.; Graham, D.W.; Hermanowski-Vosatka, A.; LeGrand, C.B.; Mundt, S.S.; Robbins, M.A.; Schaeffer, J.M.; Slossberg, L.H.; Szymonifka, M.J.; Thieringer, R.; Wright, S.D.; Balkovec, J.M.
Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
Bioorg. Med. Chem. Lett.
15
4359-4362
2005
Mus musculus (P51661), Homo sapiens (P80365)
brenda
Jang, C.; Obeyesekere, V.R.; Dilley, R.J.; Alford, F.P.; Inder, W.J.
11beta Hydroxysteroid dehydrogenase type 1 is expressed and is biologically active in human skeletal muscle
Clin. Endocrinol. (Oxf.)
65
800-805
2006
Homo sapiens
brenda
Basu, R.; Edgerton, D.S.; Singh, R.J.; Cherrington, A.; Rizza, R.A.
Splanchnic cortisol production in dogs occurs primarily in the liver: evidence for substantial hepatic specific 11beta hydroxysteroid dehydrogenase type 1 activity
Diabetes
55
3013-3019
2006
Canis lupus familiaris
brenda
Groyer, G.; Eychenne, B.; Girard, C.; Rajkowski, K.; Schumacher, M.; Cadepond, F.
Expression and functional state of the corticosteroid receptors and 11 beta-hydroxysteroid dehydrogenase type 2 in Schwann cells
Endocrinology
147
4339-4350
2006
Rattus norvegicus
brenda
Ozaki, Y.; Higuchi, M.; Miura, C.; Yamaguchi, S.; Tozawa, Y.; Miura, T.
Roles of 11beta-hydroxysteroid dehydrogenase in fish spermatogenesis
Endocrinology
147
5139-5146
2006
Anguilla japonica (Q05KC1)
brenda
Ohshima, M.; Ohno, S.; Nakajin, S.
Inhibitory effects of some possible endocrine-disrupting chemicals on the isozymes of human 11beta-hydroxysteroid dehydrogenase and expression of their mRNA in gonads and adrenal glands
Environ. Sci.
12
219-230
2005
Homo sapiens
brenda
Claus, R.; Wagner, A.; Lambert, T.
Characterization of 11beta-hydroxysteroid dehydrogenase activity in testicular tissue of control and GnRH-immunized boars as a possible regulator of spermatogenesis
Exp. Clin. Endocrinol. Diabetes
113
262-267
2005
Sus scrofa (Q8MKG1)
brenda
Carvajal, C.A.; Romero, D.G.; Mosso, L.M.; Gonzalez, A.A.; Campino, C.; Montero, J.; Fardella, C.E.
Biochemical and genetic characterization of 11 beta-hydroxysteroid dehydrogenase type 2 in low-renin essential hypertensives
J. Hypertens.
23
71-77
2005
Homo sapiens
brenda
Arampatzis, S.; Kadereit, B.; Schuster, D.; Balazs, Z.; Schweizer, R.A.; Frey, F.J.; Langer, T.; Odermatt, A.
Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species
J. Mol. Endocrinol.
35
89-101
2005
Canis lupus familiaris, Mus musculus, Rattus norvegicus, Homo sapiens (P28845), Homo sapiens (P80365), Cavia porcellus (Q6QLL4), Mesocricetus auratus (Q6R0J2)
brenda
Mazancova, K.; Kopecky, M.; Miksik, I.; Pacha, J.
11beta-Hydroxysteroid dehydrogenase in the heart of normotensive and hypertensive rats
J. Steroid Biochem. Mol. Biol.
94
273-277
2005
Rattus norvegicus
brenda
Latif, S.A.; Pardo, H.A.; Hardy, M.P.; Morris, D.J.
Endogenous selective inhibitors of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2 of adrenal origin
Mol. Cell. Endocrinol.
243
43-50
2005
Ovis aries
brenda
Temkin, S.; Nacharaju, V.L.; Hellman, M.; Lee, Y.C.; Abulafia, O.
Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer
Steroids
7
1019-1023
2006
Homo sapiens
-
brenda
Sadosky, P.W.; Scammell, J.G.
Increased production of 11beta-hydroxysteroid dehydrogenase type 2 in the kidney microsomes of squirrel monkeys (Saimiri spp.)
Comp. Med.
58
180-187
2008
Saimiri, Sus scrofa, Oryctolagus cuniculus (P51976)
brenda
Balazs, Z.; Schweizer, R.A.; Frey, F.J.; Rohner-Jeanrenaud, F.; Odermatt, A.
DHEA induces 11 -HSD2 by acting on CCAAT/enhancer-binding proteins
J. Am. Soc. Nephrol.
19
92-101
2008
Rattus norvegicus
brenda
Ito-Kobayashi, M.; Aoyagi, A.; Tanaka, I.; Muramatsu, Y.; Umetani, M.; Takatsu, T.
Sterenin A, B, C and D, novel 11beta-hydroxysteroid dehydrogenase type 1 inhibitors from Stereum sp. SANK 21205
J. Antibiot.
61
128-135
2008
Homo sapiens
brenda
Jang, C.; Obeyesekere, V.R.; Dilley, R.J.; Krozowski, Z.; Inder, W.J.; Alford, F.P.
Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes
J. Clin. Endocrinol. Metab.
92
3314-3320
2007
Homo sapiens
brenda
Sloboda, D.M.; Moss, T.J.; Li, S.; Matthews, S.G.; Challis, J.R.; Newnham, J.P.
Expression of glucocorticoid receptor, mineralocorticoid receptor, and 11beta-hydroxysteroid dehydrogenase 1 and 2 in the fetal and postnatal ovine hippocampus: ontogeny and effects of prenatal glucocorticoid exposure
J. Endocrinol.
197
213-220
2008
Ovis aries
brenda
Gong, R.; Morris, D.J.; Brem, A.S.
Human renal 11beta-hydroxysteroid dehydrogenase 1 functions and co-localizes with COX-2
Life Sci.
82
631-637
2008
Homo sapiens
brenda
Garbrecht, M.R.; Klein, J.M.; McCarthy, T.A.; Schmidt, T.J.; Krozowski, Z.S.; Snyder, J.M.
11-beta Hydroxysteroid dehydrogenase type 2 in human adult and fetal lung and its regulation by sex steroids
Pediatr. Res.
62
26-31
2007
Homo sapiens
brenda
Chandras, C.; Harris, T.E.; Bernal, A.L.; Abayasekara, D.R.; Michael, A.E.
PTGER1 and PTGER2 receptors mediate regulation of progesterone synthesis and type 1 11beta-hydroxysteroid dehydrogenase activity by prostaglandin E2 in human granulosa-lutein cells
J. Endocrinol.
194
595-602
2007
Homo sapiens
brenda
Johansson, L.; Fotsch, C.; Bartberger, M.D.; Castro, V.M.; Chen, M.; Emery, M.; Gustafsson, S.; Hale, C.; Hickman, D.; Homan, E.; Jordan, S.R.; Komorowski, R.; Li, A.; McRae, K.; Moniz, G.; Matsumoto, G.; Orihuela, C.; Palm, G.; Veniant, M.; Wang, M.; Williams, M.; Zhang, J.
2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice
J. Med. Chem.
51
2933-2943
2008
Homo sapiens
brenda
Milagro, F.I.; Campion, J.; Martinez, J.A.
11-Beta hydroxysteroid dehydrogenase type 2 expression in white adipose tissue is strongly correlated with adiposity
J. Steroid Biochem. Mol. Biol.
104
81-84
2007
Rattus norvegicus
brenda
Honda, Y.; Ohno, S.; Nakajin, S.
Leydig cells from neonatal pig testis abundantly express 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2 and effectively inactivate cortisol to cortisone
J. Steroid Biochem. Mol. Biol.
108
91-101
2008
Sus scrofa
brenda
Sakumoto, R.; Ito, S.; Okuda, K.
Changes in expression of 11beta-hydroxysteroid dehydrogenase type-1, type-2 and glucocorticoid receptor mRNAs in porcine corpus luteum during the estrous cycle
Mol. Reprod. Dev.
75
925-930
2008
Sus scrofa
brenda
Sharp, V.; Thurston, L.M.; Fowkes, R.C.; Michael, A.E.
11Beta-hydroxysteroid dehydrogenase enzymes in the testis and male reproductive tract of the boar (Sus scrofa domestica) indicate local roles for glucocorticoids in male reproductive physiology
Reproduction
134
473-482
2007
Sus scrofa
brenda
Klusonova, P.; Kucka, M.; Miksik, I.; Bryndova, J.; Pacha, J.
Chicken 11beta-hydroxysteroid dehydrogenase type 2: partial cloning and tissue distribution
Steroids
73
348-355
2008
Gallus gallus
brenda
Henschkowski, J.; Stuck, A.E.; Frey, B.M.; Gillmann, G.; Dick, B.; Frey, F.J.; Mohaupt, M.G.
Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) activity in hypertensive patients
Am. J. Hypertens.
21
644-649
2008
Homo sapiens
brenda
Hong, D.; Li, X.W.; Lian, Q.Q.; Lamba, P.; Bernard, D.J.; Hardy, D.O.; Chen, H.X.; Ge, R.S.
Mono-(2-ethylhexyl) phthalate (MEHP) regulates glucocorticoid metabolism through 11beta-hydroxysteroid dehydrogenase 2 in murine gonadotrope cells
Biochem. Biophys. Res. Commun.
389
305-309
2009
Mus musculus
brenda
Zhao, B.; Chu, Y.; Huang, Y.; Hardy, D.O.; Lin, S.; Ge, R.S.
Structure-dependent inhibition of human and rat 11beta-hydroxysteroid dehydrogenase 2 activities by phthalates
Chem. Biol. Interact.
183
79-84
2010
Homo sapiens, Rattus norvegicus
brenda
Mericq, V.; Medina, P.; Kakarieka, E.; Marquez, L.; Johnson, M.C.; Iniguez, G.
Differences in expression and activity of 11beta-hydroxysteroid dehydrogenase type 1 and 2 in human placentas of term pregnancies according to birth weight and gender
Eur. J. Endocrinol.
161
419-425
2009
Homo sapiens
brenda
Chen, B.B.; Lin, H.; Hu, G.X.; Su, Y.; Zhou, H.Y.; Lian, Q.Q.; Cai, H.; Hardy, D.O.; Gu, D.Y.; Ge, R.S.
The (+)- and (-)-gossypols potently inhibit human and rat 11beta-hydroxysteroid dehydrogenase type 2
J. Steroid Biochem. Mol. Biol.
113
177-181
2009
Homo sapiens, Rattus norvegicus
brenda
Classen-Houben, D.; Schuster, D.; Da Cunha, T.; Odermatt, A.; Wolber, G.; Jordis, U.; Kueenburg, B.
Selective inhibition of 11beta-hydroxysteroid dehydrogenase 1 by 18alpha-glycyrrhetinic acid but not 18beta-glycyrrhetinic acid
J. Steroid Biochem. Mol. Biol.
113
248-252
2009
Homo sapiens
brenda
Sharp, V.; Thurston, L.M.; Fowkes, R.C.; Michael, A.E.
Expression and activities of 11betaHSD enzymes in the testes and reproductive tracts of sexually immature male pigs
J. Steroid Biochem. Mol. Biol.
115
98-106
2009
Sus scrofa
brenda
Chapman, K.E.; Coutinho, A.E.; Gray, M.; Gilmour, J.S.; Savill, J.S.; Seckl, J.R.
The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in the inflammatory response
Mol. Cell. Endocrinol.
301
123-131
2009
Homo sapiens, Mus musculus
brenda
Gong, R.; Morris, D.J.; Brem, A.S.
Variable expression of 11beta Hydroxysteroid dehydrogenase (11beta-HSD) isoforms in vascular endothelial cells
Steroids
73
1187-1196
2008
Bos taurus, Homo sapiens, Rattus norvegicus
brenda
Stanetty, C.; Czollner, L.; Koller, I.; Shah, P.; Gaware, R.; Cunha, T.D.; Odermatt, A.; Jordis, U.; Kosma, P.; Classen-Houben, D.
Synthesis of novel 3-amino and 29-hydroxamic acid derivatives of glycyrrhetinic acid as selective 11beta-hydroxysteroid dehydrogenase 2 inhibitors
Bioorg. Med. Chem.
18
7522-7541
2010
Homo sapiens
brenda
Kim, C.H.; Cho, Y.S.
Selection and optimization of MCF-7 cell line for screening selective inhibitors of 11beta-hydroxysteroid dehydrogenase 2
Cell Biochem. Funct.
28
440-447
2010
Homo sapiens
brenda
Xu, D.; Sheng, Y.; Zhou, Z.Y.; Liu, R.; Leng, Y.; Liu, J.K.
Sesquiterpenes from cultures of the basidiomycete Clitocybe conglobata and their 11 beta-hydroxysteroid dehydrogenase inhibitory activity
Chem. Pharm. Bull.
57
433-435
2009
Homo sapiens, Mus musculus
brenda
Zhang, L.; Shen, Y.; Zhu, H.J.; Wang, F.; Leng, Y.; Liu, J.K.
Pentanol derivatives from basidiomycete Catathelasma imperiale and their 11beta-hydroxysteroid dehydrogenases inhibitory activity
J. Antibiot.
62
239-242
2009
Homo sapiens, Mus musculus
brenda
Zhang, L.; Shen, Y.; Wang, F.; Leng, Y.; Liu, J.K.
Rare merosesquiterpenoids from basidiomycete Craterellus odoratus and their inhibition of 11beta-hydroxysteroid dehydrogenases
Phytochemistry
71
100-103
2010
Homo sapiens
brenda
Kratschmar, D.V.; Vuorinen, A.; Da Cunha, T.; Wolber, G.; Classen-Houben, D.; Doblhoff, O.; Schuster, D.; Odermatt, A.
Characterization of activity and binding mode of glycyrrhetinic acid derivatives inhibiting 11beta-hydroxysteroid dehydrogenase type 2
J. Steroid Biochem. Mol. Biol.
125
129-142
2011
Homo sapiens (P80365)
brenda
Zhao, B.; Lian, Q.; Chu, Y.; Hardy, D.O.; Li, X.K.; Ge, R.S.
The inhibition of human and rat 11beta-hydroxysteroid dehydrogenase 2 by perfluoroalkylated substances
J. Steroid Biochem. Mol. Biol.
125
143-147
2011
Rattus norvegicus, Homo sapiens (P80365)
brenda
Hu, G.; Lin, H.; Lian, Q.; Zhou, S.; Guo, J.; Zhou, H.; Chu, Y.; Ge, R.
Curcumin as a potent and selective inhibitor of 11beta-hydroxysteroid dehydrogenase 1: improving lipid profiles in high-fat-diet-treated rats
PLoS ONE
8
e49976
2013
Homo sapiens (P80365)
brenda
Guan, H.; Sun, K.; Yang, K.
The ERK1/2 signaling pathway regulates 11beta-hydroxysteroid dehydrogenase type 2 expression in human trophoblast cells through a transcriptional mechanism
Biol. Reprod.
89
92
2013
Homo sapiens (P80365)
brenda
Green, B.B.; Armstrong, D.A.; Lesseur, C.; Paquette, A.G.; Guerin, D.J.; Kwan, L.E.; Marsit, C.J.
The role of placental 11-beta hydroxysteroid dehydrogenase type 1 and type 2 methylation on gene expression and infant birth weight
Biol. Reprod.
92
149
2015
Homo sapiens (P28845), Homo sapiens (P80365)
brenda
Ergang, P.; Kuzelova, A.; Sotak, M.; Klusonova, P.; Makal, J.; Pacha, J.
Distinct effect of stress on 11beta-hydroxysteroid dehydrogenase type 1 and corticosteroid receptors in dorsal and ventral hippocampus
Physiol. Res.
63
255-261
2014
Rattus norvegicus (P16232)
brenda
Heussner, K.; Ruebner, M.; Huebner, H.; Rascher, W.; Menendez-Castro, C.; Hartner, A.; Fahlbusch, F.B.; Rauh, M.
Species differences of 11beta-hydroxysteroid dehydrogenase type 2 function in human and rat term placenta determined via LC-MS/MS
Placenta
37
79-84
2016
Homo sapiens (P80365), Rattus norvegicus, Rattus norvegicus Wistar
brenda
Huebner, H.; Heussner, K.; Ruebner, M.; Schmid, M.; Nadal, J.; Woelfle, J.; Hartner, A.; Menendez-Castro, C.; Rauh, M.; Beckmann, M.W.; Kehl, S.; Fahlbusch, F.B.
Influence of labor on direct and indirect determinants of placental 11beta-hydroxysteroid dehydrogenase activity
Arch. Gynecol. Obstet.
303
401-408
2021
Homo sapiens (P80365)
brenda